Finding no magic for 'Merlin,' Sir Evans shifts focus

Sir Christopher Evans' is scrapping Merlin Biosciences and transferring the early-stage venture funds to the newly-formed Excalibur, which will shift focus to late-stage therapies. That's bitter news to start-ups in the UK, which have long been able to tap into the seed funds offered by Merlin. Evans plans to raise a new fund with £100 million to invest in a range of companies spanning everything from specialty pharma to surgical equipment makers.

Many early-stage biotechs are "fraught with difficulty" and may have to consolidate, Evans told the Financial Times. Merlin's three funds are worth more than £450 million.

- read the article in the Financial Times

Related Articles:
Tips for funding a biotech start-up. Report
VC firm looks to early-stage research projects. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.